Sandbox:Mitra3: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
{{familytree | | | C01 | | | C02 | | | C03 | | C04 | | C05 | | C06 | | | | {{familytree | | | C01 | | | C02 | | | C03 | | C04 | | C05 | | C06 | | | | ||
|C01=<div style="float: left; text-align: left; width: 12em; padding:1em;"> •'''Thrmobolytics''' <br> •'''Percutaneous coronary intervention (PCI)''' <br> | |C01=<div style="float: left; text-align: left; width: 12em; padding:1em;"> •'''Thrmobolytics''' <br> •'''Percutaneous coronary intervention (PCI)''' <br> | ||
|C02= • Avoidance of preload reducing agents, such as:<br> | |C02= • '''Avoidance of preload reducing agents''', such as:<br> | ||
:❑Nitrates | :❑Nitrates | ||
:❑Diuretics | :❑Diuretics | ||
:❑Morphin | :❑Morphin | ||
|C03=• '''Systemic or pulmonary vasodilators:'''< | |C03=• '''Systemic or pulmonary vasodilators:'''<br> | ||
:❑Inhaled nitric oxide<be> | :❑Inhaled nitric oxide<be> | ||
|C04=• '''In patients with bradyarrhthmias:'''<br> | |C04=• '''In patients with bradyarrhthmias:'''<br> | ||
:❑Atropine | |||
:❑Pacemaker | |||
|C05=• '''In patients with refractory hypotension:'''<br> | |||
|C06= May be needed in patients with cardiogenic shock secondary to RVMI}} | |||
{{familytree | | | | | | | | | | | |!| | | |!| }} | {{familytree | | | | | | | | | | | |!| | | |!| }} | ||
{{familytree/end}} | {{familytree/end}} | ||
Revision as of 17:57, 3 August 2020
| Therapuetic Considerations in RVMI | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reperfusion | Maintenance of RV preload | Decreased RV afterload | Restoring Rate/Rhythm and AV synchrony | Inotropic support | Mechanical Circulatory Support | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
•Thrmobolytics •Percutaneous coronary intervention (PCI) | • Avoidance of preload reducing agents, such as:
| • Systemic or pulmonary vasodilators: | • In patients with bradyarrhthmias: | • In patients with refractory hypotension: | May be needed in patients with cardiogenic shock secondary to RVMI | {{{ }}} | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||